Story perspectives

Pfizer Sues Novo Nordisk Over Obesity Drug Merger Dispute

11/2/2025

43 5

Summary

Story summary

Pfizer filed a Delaware lawsuit against Metsera and Novo Nordisk, alleging Novo's bid breaches the merger agreement and seeking a temporary restraining order.
Pfizer claims Novo's offer illegally seeks to suppress competition in the obesity drug market.
The suit follows early antitrust clearance from the FTC for Pfizer's $7.3 billion Metsera acquisition.
Metsera and Novo deny Pfizer's allegations, and Pfizer argues the proposal with a special dividend violates Delaware law.

1 of 1

Story summary

Pfizer filed a Delaware lawsuit against Metsera and Novo Nordisk, alleging Novo's bid breaches the merger agreement and seeking a temporary restraining order.
Pfizer claims Novo's offer illegally seeks to suppress competition in the obesity drug market.
The suit follows early antitrust clearance from the FTC for Pfizer's $7.3 billion Metsera acquisition.
Metsera and Novo deny Pfizer's allegations, and Pfizer argues the proposal with a special dividend violates Delaware law.